Tim Bertram, Tengion's chief scientific officer and acting CEO, said that the time of regenerative medicine has come and that the technology will continue to thrive in coming years. At the Regenerative Medicine Roundtable, Bertram said companies should focus on the commercial applications of products in order to draw funding. Abner Mhashilkar, medical translational officer at the Wake Forest Institute for Regenerative Medicine who previously worked for venture capital firm Toucan Capital, said that funding was available for regenerative medicine firms but that most venture capitalists want to see a return on investment within six years.

Full Story:

Related Summaries